Provided by Tiger Trade Technology Pte. Ltd.

SILO PHARMA INC.

0.4010
+0.00100.25%
Post-market: 0.4000-0.0010-0.25%17:11 EST
Volume:64.40K
Turnover:26.31K
Market Cap:5.34M
PE:-0.49
High:0.4150
Open:0.4100
Low:0.4000
Close:0.4000
52wk High:3.37
52wk Low:0.3601
Shares:13.32M
Float Shares:13.12M
Volume Ratio:0.38
T/O Rate:0.49%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.8241
EPS(LYR):-1.1936
ROE:-86.11%
ROA:-44.37%
PB:1.07
PE(LYR):-0.34

Loading ...

Silo Pharma updates strategic agreement with Fireblocks

TIPRANKS
·
Sep 30

Silo Pharma Inc. Announces Implementation of Strategic Agreement with Fireblocks for Crypto Treasury Management

Reuters
·
Sep 30

Silo Pharma Updates Strategic Agreement With Fireblocks to Secure Crypto Treasury Management

THOMSON REUTERS
·
Sep 30

Silo Pharma Signs Strategic Agreement With Fireblocks to Advance Crypto Treasury Strategy Acquisition and Security

THOMSON REUTERS
·
Sep 23

Silo Pharma Inc. Signs Agreement with Fireblocks for Crypto Treasury Security

Reuters
·
Sep 23

Silo Pharma Announces Initial Investment in Ethereum and Solana Under Cryptocurrency Treasury Strategy

THOMSON REUTERS
·
Sep 16

Silo Pharma Secures Japanese Patent for PTSD Drug SPC-15, Expanding Global IP Portfolio

Reuters
·
Sep 09

Silo Pharma Inc. Announces Date for 2025 Annual Shareholders Meeting

Reuters
·
Sep 06

BRIEF-Silo Pharma Secures Australian Patent Covering Licensed Ptsd Drug Candidate Expanding Global Ip Portfolio

Reuters
·
Sep 03

Silo Pharma Inc. Announces Date for 2025 Annual Meeting of Shareholders

Reuters
·
Aug 26

Silo Pharma’s Ptsd Candidate Spc-15 Achieves Positive Safety Milestone, Paving Way for Accelerated Clinical Trials Under 505(B)(2) Pathway

THOMSON REUTERS
·
Aug 19

Silo Pharma Inc - Spc-15 Intranasal Spray Shows Safety With No Toxicities

THOMSON REUTERS
·
Aug 19

Silo Pharma Inc. Issues 750,000 Shares for Asset Acquisition from MAVS Holdings LLC

Reuters
·
Jul 30

Silo Pharma Inc. Completes Dosing in Safety Study of PTSD Drug SPC-15, Awaits Bioanalytical Results

Reuters
·
Jul 16

Silo Pharma Inc. Awaits Pre-Clinical Data for SPC-15, Plans IND Submission for PTSD Drug in 2025 with Potential Phase 1 Trials by 2026

Reuters
·
Jul 07

Silo Pharma Inc. Faces Nasdaq Non-Compliance Over Minimum Bid Price Rule

Reuters
·
Jul 04

Silo Pharma, Hoth Therapeutics to Launch Joint Venture for Obesity Treatment

MT Newswires Live
·
Jun 25

BRIEF-Silo Pharma announces Formation Of Joint Venture With Hoth Therapeutics

Reuters
·
Jun 25